search
Back to results

Post-approval Study of the DURALOC® Option Ceramic-on-Ceramic Hip Prosthesis System

Primary Purpose

Non-inflammatory Joint Disease, Osteoarthritis, Avascular Necrosis

Status
Terminated
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Total hip replacement/arthroplasty
Sponsored by
DePuy Orthopaedics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non-inflammatory Joint Disease focused on measuring Total hip replacement, Total hip arthroplasty

Eligibility Criteria

21 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Skeletally mature
  • Provide informed consent
  • Sufficient acetabular and femoral bone stock to seat the prosthesis
  • Willing and able to return for follow-up as specified by the study protocol
  • Willing and able to complete the hip outcomes questionnaire and quality of life survey (SF12)
  • Undergo hip replacement due to non-inflammatory joint disease, including osteoarthritis, avascular necrosis, congenital hip dysplasia or post-traumatic arthritis.

Exclusion Criteria:

  • Diagnosis of inflammatory arthritides such as rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, systemic lupus, erythematosis etc.
  • Active infections that may spread to other systems such as osteomyelitis, pyogenic infection of the hip joint overt infection, etc.
  • Loss of musculature, neuromuscular compromise or vascular deficiency in the affected limb which impedes evaluation.
  • Poor bone quality (e.g. osteoporosis) such that there is concern about the ability of inadequate bone stock to support the implant.
  • Morbid obesity
  • Involvement in high levels of activity or participation in active sports
  • Involvement in heavy manual labor employment
  • Increased likelihood of falls due to concomitant illnesses or impairment
  • Pregnancy, breast-feeding, a prisoner, mentally incompetent, a known alcohol or drug abuser
  • Diagnosis of metabolic disorders or receiving systemic pharmacological treatments leading to progressive deterioration of solid bone support for the implant
  • Known history of conditions that may interfere with the total hip arthroplasty survival or outcome (e.g. Paget's disease, Charcot's disease)
  • Known presence of active metastatic or neoplastic disease
  • Known allergic reactions to implant materials (e.g. ceramic, metal)
  • Known history of tissue reactions to implant corrosion or implant wear debris
  • Disabilities of other joints that impedes evaluation (e.g. knees, ankles)
  • Known presence of highly communicable disease or diseases that may limit follow-up (e.g. immunocompromised conditions, hepatitis, active tuberculosis etc.)
  • Previous prosthetic hip replacement device (any type including THA, surface replacement arthroplasty, endoprosthesis etc.)

Sites / Locations

  • Northside Hospital
  • Memorial Hospital
  • St. John's Hospital
  • Fairview Hospital
  • St. Luke's Hospital
  • Flower Hospital

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Duraloc Option COC Hip

Arm Description

Outcomes

Primary Outcome Measures

Survivorship

Secondary Outcome Measures

Study subject SF-12 health survey
SF-12 Health survey and Subject Outcomes Questionnaire
Hip Function (using Harris Hip Score)

Full Information

First Posted
October 17, 2007
Last Updated
November 29, 2021
Sponsor
DePuy Orthopaedics
search

1. Study Identification

Unique Protocol Identification Number
NCT00546598
Brief Title
Post-approval Study of the DURALOC® Option Ceramic-on-Ceramic Hip Prosthesis System
Official Title
DURALOC® Option Ceramic-on-Ceramic Hip Prosthesis System PMA Post-approval Study
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Terminated
Why Stopped
Sponsor withdrew PMA
Study Start Date
January 1, 2006 (Actual)
Primary Completion Date
April 1, 2014 (Actual)
Study Completion Date
April 1, 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
DePuy Orthopaedics

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is being conducted to gather medium and long-term information regarding the performance and safety of the commercially available DURALOC® Option Ceramic-on-Ceramic Hip Prosthesis System.
Detailed Description
This two-phased study on hip arthroplasty consists of a clinical follow-up phase and a clinical outcomes phase. The DURALOC® Option Ceramic-on-Ceramic Hip Prosthesis System consists of: a modular ceramic bearing insert that secures to a titanium metal alloy DURALOC® Option Acetabular Shell via a taper locking mechanism; and a ceramic femoral head that is attached to a conventional femoral stem to complete the total hip prosthesis device configuration.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-inflammatory Joint Disease, Osteoarthritis, Avascular Necrosis, Congenital Hip Dysplasia, Post-traumatic Arthritis
Keywords
Total hip replacement, Total hip arthroplasty

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
106 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Duraloc Option COC Hip
Arm Type
Other
Intervention Type
Device
Intervention Name(s)
Total hip replacement/arthroplasty
Other Intervention Name(s)
DURALOC® Option Ceramic-on-Ceramic Hip system
Intervention Description
Hip replacement
Primary Outcome Measure Information:
Title
Survivorship
Time Frame
5 years
Secondary Outcome Measure Information:
Title
Study subject SF-12 health survey
Time Frame
1, 2 ,3, 4 and 5 years
Title
SF-12 Health survey and Subject Outcomes Questionnaire
Time Frame
6, 7, 8, 9 and 10 years
Title
Hip Function (using Harris Hip Score)
Time Frame
6 weeks, 6 months and 1, 2, 3, 4, and 5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Skeletally mature Provide informed consent Sufficient acetabular and femoral bone stock to seat the prosthesis Willing and able to return for follow-up as specified by the study protocol Willing and able to complete the hip outcomes questionnaire and quality of life survey (SF12) Undergo hip replacement due to non-inflammatory joint disease, including osteoarthritis, avascular necrosis, congenital hip dysplasia or post-traumatic arthritis. Exclusion Criteria: Diagnosis of inflammatory arthritides such as rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, systemic lupus, erythematosis etc. Active infections that may spread to other systems such as osteomyelitis, pyogenic infection of the hip joint overt infection, etc. Loss of musculature, neuromuscular compromise or vascular deficiency in the affected limb which impedes evaluation. Poor bone quality (e.g. osteoporosis) such that there is concern about the ability of inadequate bone stock to support the implant. Morbid obesity Involvement in high levels of activity or participation in active sports Involvement in heavy manual labor employment Increased likelihood of falls due to concomitant illnesses or impairment Pregnancy, breast-feeding, a prisoner, mentally incompetent, a known alcohol or drug abuser Diagnosis of metabolic disorders or receiving systemic pharmacological treatments leading to progressive deterioration of solid bone support for the implant Known history of conditions that may interfere with the total hip arthroplasty survival or outcome (e.g. Paget's disease, Charcot's disease) Known presence of active metastatic or neoplastic disease Known allergic reactions to implant materials (e.g. ceramic, metal) Known history of tissue reactions to implant corrosion or implant wear debris Disabilities of other joints that impedes evaluation (e.g. knees, ankles) Known presence of highly communicable disease or diseases that may limit follow-up (e.g. immunocompromised conditions, hepatitis, active tuberculosis etc.) Previous prosthetic hip replacement device (any type including THA, surface replacement arthroplasty, endoprosthesis etc.)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dave Whalen, BS, DC
Organizational Affiliation
DePuy Orthopaedics
Official's Role
Study Director
Facility Information:
Facility Name
Northside Hospital
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30342
Country
United States
Facility Name
Memorial Hospital
City
Springfield
State/Province
Illinois
ZIP/Postal Code
62781
Country
United States
Facility Name
St. John's Hospital
City
Springfield
State/Province
Illinois
ZIP/Postal Code
62781
Country
United States
Facility Name
Fairview Hospital
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44111
Country
United States
Facility Name
St. Luke's Hospital
City
Maumee
State/Province
Ohio
ZIP/Postal Code
43537
Country
United States
Facility Name
Flower Hospital
City
Sylvania
State/Province
Ohio
ZIP/Postal Code
43560
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Post-approval Study of the DURALOC® Option Ceramic-on-Ceramic Hip Prosthesis System

We'll reach out to this number within 24 hrs